US pledges to provide non-profit lenacapavir drug to treat HIV/AIDS

The US State Department has announced plans to bring the HIV/AIDS treatment drug lenacapavir from biopharmaceutical company Gilead Sciences Inc to the market "at cost".

Lenacapavir has been shown to be nearly 100% effective in preventing HIV. Photo: theguardian.com

The US State Department has announced plans to market the HIV/AIDS treatment drug lenacapavir from biopharmaceutical company Gilead Sciences Inc. "at cost" in countries heavily affected by the disease, with the goal of providing the drug to 2 million people within 3 years.

At a press conference, US government officials and Gilead Sciences representatives said the company will provide lenacapavir for non-profit use to the Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria and the US President's Emergency Plan for AIDS Relief (PEPFAR).

In July, Gilead Sciences and the Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria said they had finalized plans to provide the drug to low-income countries, despite not receiving funding from PEPFAR.

Lenacapavir, given by injection twice a year, has significant benefits for women who are breastfeeding and pregnant.

According to Mr. Lewin, the US State Department has agreed to provide the above drug to 12 countries, but has not announced exactly which countries.

PV (synthesis)

Source: https://baohaiphong.vn/my-cam-ket-cung-cap-phi-loi-nhuan-thuoc-lenacapavir-dieu-tri-hiv-aids-520005.html